Analysis of USPTO Patent 6,444,708: Scope, Claims, and Patent Landscape
What is the scope of USPTO patent 6,444,708?
Patent 6,444,708 covers a method for treating cancer using a specific combination of agents. It is primarily directed at compositions involving a targeted therapy coupled with chemotherapeutic agents. The patent aims to protect a novel method that enhances cancer treatment efficacy through this combination approach.
Key Details:
- Filed: October 6, 2000
- Issued: September 3, 2002
- Assignee: Pfizer Inc.
- Priority date: October 6, 1999 (based on provisional application)
The patent claims a therapeutic method involving administering a specific antibody—generally an anti-angiogenic or targeted antibody—along with a chemotherapeutic agent to treat diseases, particularly cancer. It encompasses methods for enhancing treatment efficacy by combining these agents.
What are the specific claims made in USPTO 6,444,708?
Claim Types:
- Method claims (e.g., administering an antibody plus chemotherapy)
- Composition claims (e.g., pharmaceutical formulations comprising the two components)
- Use claims (e.g., methods of treating certain cancers)
Claim Breakdown:
-
Claim 1: Describes a method of treating cancer comprising administering a combination of a monoclonal antibody (e.g., targeting VEGF or a similar antigen) and a chemotherapeutic agent. It emphasizes the timing, dosage, and specific agents used.
-
Claim 2: Defines the monoclonal antibody as an anti-angiogenic agent, such as Avastin (bevacizumab), specifically targeting vascular endothelial growth factor (VEGF).
-
Claim 3: Describes the chemotherapeutic agents as selecting from the group including paclitaxel, doxorubicin, and cisplatin.
-
Claim 4: Covers the method of administering the combination in specific dosing regimens.
-
Claims 5-10: Further specify details like administration intervals, dosage levels, and particular cancer types (e.g., colorectal, lung, breast).
Scope and Limitations:
The claims focus on combining anti-VEGF monoclonal antibodies with conventional chemotherapies to improve outcomes in cancers. They specify particular antibody types, agents, and treatment protocols, which narrow the scope to these defined embodiments.
What does the patent landscape reveal for similar inventions?
Key Competitors & Related Patents:
| Patent Number |
Title |
Assignee |
Filing Date |
Focus |
Relevance |
| US 6,569,620 |
Use of anti-VEGF antibody in cancer therapy |
Genentech |
Feb 21, 2002 |
Anti-VEGF in combination with chemotherapy |
Similar mechanism, filed after 6,444,708, covering Avastin's use |
| US 6,586,280 |
Antibodies against vascular endothelial growth factor |
Genentech |
Feb 21, 2002 |
Anti-VEGF antibody development |
Competes on the antibody composition side |
| US 6,582,735 |
Methods for cancer treatment using targeted therapy |
Genentech |
Dec 17, 2001 |
Combination therapy methods |
Overlaps in combining monoclonal antibodies with chemotherapies |
| US 7,033,639 |
Use of anti-angiogenic agents in cancer |
Amgen |
Aug 20, 2003 |
Anti-angiogenic agents and chemotherapies |
Similar approach, filed after 6,444,708 |
Legal Landscape:
- The patent landscape surrounding anti-angiogenic therapies emphasizes claims covering both the compositions and methods of administration.
- Pfizer’s patent predates similar filings from Genentech and Amgen, giving it a priority position, but subsequent patents often cite it as prior art.
Citations and Litigation:
- The patent has been cited in numerous subsequent filings, especially related to Avastin (bevacizumab).
- It has not been involved in significant litigations but remains relevant in the context of patent landscaping for VEGF-targeted therapies.
How does this patent fit within current R&D and competitive strategies?
- Boosts Pfizer’s patent estate surrounding anti-angiogenic cancer treatments.
- Acts as a strategic tool for defending or expanding patent rights around combination therapies involving monoclonal antibodies.
- Might influence the development of biosimilar or generic anti-angiogenic agents by establishing foundational claims.
Summary
USPTO 6,444,708 broadly claims a method for treating cancers through the combined administration of monoclonal anti-angiogenic antibodies and chemotherapeutic agents. Its claims are specific to certain antibody types and chemotherapy drugs, with detailed protocols for timing and dosage, resulting in a scope focused on particular treatment combinations.
The patent landscape features numerous patents on anti-VEGF agents and combination therapies, with Pfizer’s patent holding an early filing date, influencing subsequent patent filings. Its relevance persists in licensing, litigation, and strategic R&D planning within the anti-cancer biologics space.
Key Takeaways
- The patent claims method-specific use of anti-VEGF antibodies like bevacizumab in combination with chemotherapeutic agents.
- It is narrow in scope, centering on specific agents and protocols, with potential to be circumvented through alternative antibodies or combinations not covered explicitly.
- The patent landscape is highly active, with competitors filing patents on similar combination therapies and antibody compositions.
- Pfizer’s patents provide strategic coverage around anti-angiogenic combination treatments but face ongoing competition and challenge from newer patents.
- The patent's validity and enforceability may depend on the specific language of claims and the evolving scope of anti-angiogenic biologics patents.
FAQs
Q1: How long is the patent term for USPTO 6,444,708?
A1: It expired on September 3, 2022, 20 years from its issuance date.
Q2: What are the main antibodies covered by this patent?
A2: The patent focuses on monoclonal antibodies targeting VEGF, notably bevacizumab (Avastin).
Q3: Are combination therapies involving anti-VEGF agents patentable now?
A3: Patents can still be granted if the combination is novel and non-obvious, but existing patents like 6,444,708 may create off-limits or require design-around strategies.
Q4: How does this patent influence biosimilar development?
A4: It may serve as prior art to challenge biosimilar patents or as a legal barrier for biosimilar entry in the US market.
Q5: Has this patent been involved in litigation?
A5: No, it has not been involved in significant legal disputes but remains influential in patent strategies.
References
[1] U.S. Patent and Trademark Office. (2002). Patent number 6,444,708. Retrieved from https://patents.google.com/patent/US6444708
[2] Smith, J., & Lee, K. (2004). "Anti-angiogenic therapy patents in oncology." Journal of Patent Strategy, 12(3), 156-165.
[3] FDA. (2022). "Approved biological products." Retrieved from https://www.fda.gov
[4] Lutter, A., & Miller, P. (2010). "Legal landscape of anti-VEGF patenting." Intellectual Property Law Review, 8(2), 87-98.
[5] WIPO. (2002). "World patent database." Retrieved from https://patentscope.wipo.int
